advertisement
Abstract #10151 Published in IGR 6-1
Safety comparison of topical brinzolamide 1% and timolol 0.5% in patients with asthma or chronic obstructive pulmonary disease
Friren B; Michaud JE; Mayolle CToday's Therapeutic Trends 2004; 22: 69-80
PURPOSE: The aim was to compare the acute effects of topical brinzolamide 1% and timolol 0.5% on pulmonary function, as measured by forced expiratory volume (FEV1) and forced vital capacity (FVC) in patients with asthma or chronic obstructive pulmonary disease (COPD). DESIGN: This randomized clinical trial was performed at a single center, with 30 patients recruited and treated as above, according to a double-masked crossover design. PATIENTS AND METHODS: In this prospective study, 61 patients were screened to find the 30 eligible patients who met the criterion of FEV1 reduction >15% from baseline after a single drop of timolol 0.5% was instilled into each eye. Assessments were made at baseline and repeated for the 30 study patients on two test occasions one week apart, alternating the administration of the two study medications in a randomized fashion. The primary endpoint was the magnitude of FEV1 reduction from baseline. The mean age of study patients was 35.4 years (33.7 in the brinzolamide-timolol group, 37.1 in the timolol-brinzolamide group; range, 22-65 years). RESULTS: Neither FEV1 nor FVC values were affected by brinzolamide 1%, compared to maximum reductions of -0.40 L/sec (p = 0.0001) in FEV1 and -0.42 L (p = 0.0008) in FVC three hours after the instillation of timolol 0.5%. Overall, blood pressure and pulse rate were unaffected. Adverse events occurred in six patients with timolol (including one non-serious asthma attack), and in one patient with brinzolamide. CONCLUSIONS: Timolol 0.5% caused a significant reduction of FEV1 in patients with asthma or COPD. Brinzolamide 1% did not cause this reduction and can therefore be safely administered to patients with asthma or COPD.
Dr. B. Friren, Laboratoires Alcon France, 4 rue Henri Ste-Claire Deville, 92563 Rueil Malmaison Cedex, France
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
